Healthcare / Medical DevicesTSXV
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-4.7M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
57.0%
↑Gross Margin
51.3%
↑Debt/Equity
-1.27
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
-1499.6%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $257949.0 · net income $-7.8M · FCF $-3.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $257949.00 | $257949.00 | $1.0M | $331403.00 | $152358.00 |
| Net Income | $-7.8M | $-7.8M | $-5.2M | $-9.4M | $-5.6M |
| EBITDA | $-4.0M | $-4.0M | $-2.9M | $-7.4M | $-3.9M |
| EPS | -0.04 | -0.04 | -0.02 | -0.05 | -0.06 |
| Gross Margin | 51.3% | 51.3% | 51.7% | 49.7% | 65.1% |
| Operating Margin | -1636.2% | -1636.2% | -510.7% | -2426.3% | -3142.3% |
| Net Margin | -3034.0% | -3034.0% | -517.5% | -2825.0% | -3661.1% |
| Balance Sheet | |||||
| Debt/Equity | -1.27 | -1.27 | -3.14 | -3.83 | -3.27 |
| Current Ratio | 1.10 | 1.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.9M | $-3.9M | $-4.7M | $-6.7M | $-2.1M |
| Returns | |||||
| ROE | 57.0% | 57.0% | 92.1% | 454.4% | 246.5% |
| Growth & Yield | |||||
| Revenue Growth | -74.5% | -74.5% | 204.7% | 117.5% | — |
| EPS Growth | -100.0% | -100.0% | 60.0% | 16.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-58.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.04
Residual
-58.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.